-Reuters
The Daily Biotech Pulse: CHMP Backs AstraZeneca’s Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Here's a roundup of top developments in the biotech space over the last 24 hours:
Related Posts
EF Hutton Maintains Buy on Jasper Therapeutics, Maintains $4 Price Target
EF Hutton analyst Michael King maintains Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $4 price target.
GrowGeneration Reports Distribution Deal With Groundwork BioAg, No Terms Disclosed
GrowGeneration Corp. (NASDAQ:GRWG) ("GrowGen") the nation's largest chain of specialty hydroponic and organic garden centers, and Groundwork BioAg, a global bio-agriculture company, today announced that
Yum! Brands Hikes Dividend By 14%
Yum! Brands, Inc. (NYSE:YUM) Board of Directors has approved a 14% increase in its quarterly dividend to $0.57 from $0.50…